Free Trial!
Today’s Best Stocks To Trade! Click Here
Stock Profiler.US, LLC welcomes Investors and Companies alike to join us in our pursuit of excellence. Companies who want to broadcast their message are encouraged to contact us at www.stockprofiler.us. Sign up for our Free Newsletter at www.stockprofiler.us.
-------------------------------------------
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA | Quote | Chart | News | PowerRating) closed at $42.26 Thursday, trading 7,552,000 shares.
Company News- June 12, 2008: Teva Announces Tentative Approval of Generic Diovan Tablets
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA | Quote | Chart | News | PowerRating) announced yesterday that the U.S. Food and Drug Administration has granted tentative approval for the Companys Abbreviated New Drug Application (ANDA) to market its generic version of Novartis hypertension treatment Diovan (Valsartan) Tablets, 40 mg, 80 mg, 160 mg and 320 mg. Final approval of this product is expected upon expiry of patent protection for the brand product in September 2012, as well as any periods of marketing exclusivity that may be awarded. The brand product had U.S. sales of approximately $1.5 billion for the twelve months ended March 30, 2008, according to IMS data.
About Teva
Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 20 pharmaceutical companies in the world and is the world's leading generic pharmaceutical company. The Company develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients, as well as animal health pharmaceutical products. Over 80 percent of Tevas sales are in North America and Europe.
-------------------------------------------
Greatbatch, Inc. (NYSE: GB | Quote | Chart | News | PowerRating) closed at $17.45 Thursday, trading 224,200 shares.
Company News- June 12, 2008: Greatbatch Announces Issuance of Key MRI Patent
Greatbatch, Inc. (NYSE: GB | Quote | Chart | News | PowerRating) announced yesterday that the U.S. Patent and Trademark Office has issued the Company patent 7,363,090. The patent provides Greatbatch with the exclusive right to incorporate band stop filtering technology into an implantable medical lead. This technology attenuates MRI-specific RF frequencies during MRI scanning, thereby eliminating the potential for lead system heating. This vital technology enables us to secure a strong position in the drive for MRI Conditional Active Implantable Medical Devices (AIMD), said Mauricio Arellano, senior vice president of Greatbatchs CRM & Neuromodulation business. John Farrell, vice president of Greatbatchs Therapy Delivery business, also noted that: This patent secures the strength and impact our on-going lead development programs will have within the stimulation markets. AIMD systems are primarily targeted for use in the cardiac rhythm management and neuromodulation markets. Greatbatch is currently completing the development of its eM-ableTM Brady (bradycardia) pacing lead, which incorporates the aforementioned technology and is expected to cross additional milestones this summer. MRI Conditional products in AIMDs are a critical initiative for device manufacturers because an MRI is often the major diagnostic tool for patients. MRI Conditional AIMDs will keep the MRI diagnostic tool in the physicians hands after an implant allowing patients to receive the greatest possible level of care. Greatbatch will showcase its eM-ableTM line of MRI Conditional technologies at this months CardioStim meeting in Nice, France and was an active exhibitor and presenter at last months annual Heart Rhythm Society meeting in San Francisco.
About eM-ableTM
eM-ableTM technology can be incorporated into implantable devices to enhance safety for patients during MRI scans. For additional information go to http://www.greatbatch.com/Medical/technologies.aspx
About Greatbatch
Greatbatch, Inc. (NYSE: GB | Quote | Chart | News | PowerRating) is a leading developer and manufacturer of critical products used in implantable medical devices for the cardiac rhythm management, neuromodulation, vascular and orthopedic markets. Additionally, Electrochem, a subsidiary of Greatbatch, is a world leader in the design and manufacture of technology solutions for some of the worlds most demanding and extreme applications.
-------------------------------------------
Laboratory Corporation of America Holdings (LabCorp) (NYSE: LH) closed at $74.02 Thursday, trading 1,715,600 shares.
Company News- June 13, 2008: LabCorp Is Scheduled to Present at the William Blair & Company 28th Annual Growth Stock Conference
Laboratory Corporation of America Holdings (LabCorp) (NYSE: LH) earlier today announced that David P. King, Chief Executive Officer and William B. (Brad) Hayes, Executive Vice President and Chief Financial Officer, are scheduled to speak at the William Blair & Company 28th Annual Growth Stock Conference in Chicago, IL. LabCorps presentation is planned for Tuesday, June 17, 2008 at 10:30 a.m. (Central Time). A live audio webcast of the presentation will be available via the Company Web site at www.labcorp.com and archived for replay.
About LabCorp
Laboratory Corporation of America Holdings, a S&P 500 company, is a pioneer in commercializing new diagnostic technologies and the first in its industry to embrace genomic testing. With annual revenues of $4.1 billion in 2007, over 26,000 employees nationwide, and more than 220,000 clients, LabCorp offers clinical assays ranging from routine blood analyses to HIV and genomic testing. LabCorp combines its expertise in innovative clinical testing technology with its Centers of Excellence: The Center for Molecular Biology and Pathology, National Genetics Institute, Inc., ViroMed Laboratories, Inc., The Center for Esoteric Testing, DIANON Systems, Inc., US LABS, and Esoterix and its Colorado Coagulation, Endocrine Sciences, and Cytometry Associates laboratories. LabCorp conducts clinical trial testing through its Esoterix Clinical Trials Services division. LabCorp clients include physicians, government agencies, managed care organizations, hospitals, clinical labs, and pharmaceutical companies. To learn more about our organization, visit our Web site at: www.labcorp.com.
-------------------------------------------
Henry Schein, Inc. (NASDAQ: HSIC | Quote | Chart | News | PowerRating) closed at $52.43 Thursday, trading 1,119,700 shares.
Company News- June 12, 2008: Henry Schein to Present at the William Blair Growth Stock Conference
Henry Schein, Inc. (NASDAQ: HSIC), the largest provider of healthcare products and services to office-based practitioners in the combined North American and European markets, announced earlier today that Stanley Bergman, Henry Scheins Chairman of the Board & Chief Executive Officer, and Steven Paladino, Henry Scheins Executive Vice President & Chief Financial Officer, will present at the William Blair Growth Stock Conference on Thursday, June 19, 2008. The Conference is being held at the Four Seasons Hotel in Chicago, Illinois. Henry Scheins presentation is scheduled to begin at 10:10 a.m. EDT and can be heard via live webcast by visiting www.henryschein.com, clicking on Investor Relations and following the link for Webcasts. A replay will be available on the Web site following the presentation.
About Henry Schein
Henry Schein, a Fortune 500 company and a member of the NASDAQ 100 Index, is recognized for its excellent customer service and highly competitive prices. The Company's four business groups Dental, Medical, International and Technology serve more than 550,000 customers worldwide, including dental practitioners and laboratories, physician practices and animal health clinics, as well as government and other institutions. The Company operates through a centralized and automated distribution network, which provides customers in more than 200 countries with a comprehensive selection of more than 90,000 national and Henry Schein private-brand products in stock, as well as more than 100,000 additional products available as special-order items. Henry Schein also offers a wide range of innovative value-added practice solutions for healthcare professionals, such as ArubA, the Companys electronic catalog and ordering system. Its leading practice-management software solutions have a user base of more than 52,000 practices, including DENTRIX, Easy Dental, Oasis and EXACT for dental practices, MicroMD for physician practices, and AVImark for animal health clinics. Headquartered in Melville, N.Y., Henry Schein employs over 12,000 people and has operations or affiliates in 20 countries. The Company's net sales reached a record $5.9 billion in 2007. For more information, visit the Henry Schein Web site at www.henryschein.com.
-------------------------------------------
Graymark Healthcare, Inc. (OTCBB: GRMH | Quote | Chart | News | PowerRating) closed at $7.00 Thursday, trading 2,500 shares.
Company News- June 12, 2008: Graymark Healthcare, Inc. Completes the Acquisitions of Sleep Development Group, LP and Nocturna Sleep, LLC
Graymark Healthcare, Inc. (OTCBB: GRMH), through its wholly owned subsidiary SDC Holdings LLC, announced earlier today it has completed the acquisitions of Sleep Development Group, LP, SDG, and Nocturna Sleep, LLC, Nocturna, pursuant to the previously announced letter of intent for each company. Graymark Healthcare, Inc. signed a letter of intent to acquire Sleep Development Group, LP in February of 2008. SDG, located in North and Central Texas, consists of three sleep centers and performed more than 4,000 sleep studies in 2007. In March of 2008, Graymark signed a letter of intent to acquire Nocturna Sleep, LLC. Located in Las Vegas, Nevada, Nocturna is a leading independent sleep diagnostic facility that is comprised of two locations housing a total of 10 beds with which to diagnose patients. Nocturna performs more than 3,000 sleep studies per year in the Las Vegas market. We are extremely pleased with the acquisitions of these two sleep diagnostic companies, stated Stanton Nelson, President and CEO of Graymark Healthcare. By acquiring SDG and Nocturna we will enter into two developing and fast growing markets that are new to our company. In addition, each of these companies has an established brand and solid customer base with excellent growth potential. We expect SDG and Nocturna to add approximately $3.5 million and $3.0 million, respectively, of incremental revenue to Graymark. Please visit the investor section of the companys Web site, www.graymarkhealthcare.com, regarding the press releases announcing the letters of intent to acquire Sleep Development Group, LP and Nocturna Sleep, LLC.
About Graymark Healthcare, Inc.
Graymark Healthcare, Inc. is a diversified medical holding company that owns and operates; independent pharmacies that serve the needs of local markets, diagnostic sleep centers that treat a wide range of sleep disorders, and a medical equipment company that provides both disposable and durable medical equipment. Graymark plans to continue its growth both internally and through strategic acquisitions within the medical industry.
-------------------------------------------
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA | Quote | Chart | News | PowerRating) closed at $14.66 Thursday, trading 71,500 shares.
Company News- June 12, 2008: Idera Pharmaceuticals to Present at BIO Business Forum 2008
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a biopharmaceutical company focused on developing therapeutics targeting Toll-Like Receptors (TLR), earlier today announced that it will present at the 2008 BIO International Convention taking place June 17-20, 2008 in San Diego, CA. The Company will discuss its TLR-targeted drug discovery and development programs and provide a general corporate update. The presentation will be delivered on Wednesday, June 18, 2008 at 3:30 p.m. PDT (12:30 p.m. EDT) in Room 5B at the San Diego Convention Center.
About Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals develops drug candidates to treat infectious diseases, autoimmune diseases, cancer, and respiratory diseases, and for use as vaccine adjuvants. Our proprietary drug candidates are designed to modulate specific Toll-like Receptors, which are a family of immune system receptors that direct immune system responses. Our pioneering DNA and RNA chemistry expertise enables us to create drug candidates for internal development and generates opportunities for multiple collaborative alliances. For more information, visit www.iderapharma.com.
-------------------------------------------
The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Stockprofiler.US affiliates has not been compensated for services rendered; Stockprofiler.US affiliates is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter.
Please consult a broker before purchasing or selling any securities mentioned herein. To view full disclaimers, go to www.stockprofiler.us) (disclaimers).
CONTACT: StockProfiler.US e-mail: info@stockprofiler.us WWW: http://www.stockprofiler.us
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
